Therefore, the aim of our study was to assay the efficacy of radioimmunoconjugates composed of the α-emitter 213Bi coupled to the anti-CD38 MAb MOR03087 in targeted treatment of MM. The gene discussed is CD38; the disease is Miyoshi myopathy.